

Remarks

The parent PCT application includes claims 1-63. By amendment herein, claims 1-63 have been canceled and claims 64-104 have been added.

The new claims present the subject matter of claims 1-63 in form for U.S. prosecution; no new matter has been introduced.

Amendments to Specification

The specification has been amended to include Applicants' claim for foreign priority, to include an Abstract on a separate page, and to include section headings where appropriate.

No new matter has been added. A copy of the amended paragraphs of the specification, with markings showing the changes, is annexed hereto.

Respectfully submitted,



Candice J. Clement  
Attorney for Applicants  
Registration Number 39,946  
Heslin & Rothenberg, P.C.  
5 Columbia Circle  
Albany, New York 12203  
Telephone: (518) 452-5600  
Facsimile: (518) 452-5579

Date: May 4, 2001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**  
**Annex to Preliminary Amendment filed May 4, 2001**

**bolding with underlining** indicates added text

A. In the specification:

1.) Page 1, the following new paragraphs are added following the title, and prior to original paragraph 1.

-- **Cross Reference to Related Applications**

**This application is a continuation of co-pending International Patent Application Number PCT/GB99/03653, filed November 5, 1999, and claims priority from GB Patent Application Number 9824306.6, filed November 5, 1998. The entire disclosures of the prior applications are incorporated herein by reference.**

**Field of the Invention** --

2.) Page 6, paragraph 6 (lines 20-24) is replaced with:

-- In another aspect, the invention provides a method for investigating a mammalian gene, which method comprises generating a test population of dendritic cells from a population of embryonic stem cells and comparing the test dendritic cells in respect of the gene.

**Brief Description of the Drawings** --

3.) Page 7, paragraph 1 (lines 1-2) is replaced with:

-- Figure 10 shows the generation of esDC stably transfected with GFP following introduction of the transgene into the parent ES cell line.

**Detailed Description of the Invention** --

4.) Page 25, paragraph 1 (line 1) is replaced with:

-- Claims

**We claim:** --

5.) A new page 29 (annexed hereto), containing the abstract, is added.

B. In the claims:

- 1.) Claims 1-63 are canceled, without prejudice.
- 2.) New claims 64-104 are added.

104050:64050